Mifepristone and Ranolazine Interaction Risks

Critical Drug Interaction Concerns

• Mifepristone should be used with extreme caution or avoided in patients taking Ranexa (ranolazine) due to the high risk of drug-drug interactions, particularly given that both medications have complex metabolic profiles and ranolazine is a P-glycoprotein substrate with known interaction risks, as recommended by The Lancet Diabetes and Endocrinology 1, 2
• Mifepristone requires expert monitoring specifically because drug-drug interactions must be carefully considered when this medication is used, according to The Lancet Diabetes and Endocrinology guidelines 1
• The Lancet Diabetes and Endocrinology guidelines explicitly state that mifepristone should be used cautiously and only by clinicians with extensive experience, emphasizing that drug-drug interactions are a major concern 2
• Mifepristone has a long half-life, which compounds interaction risks and makes management of adverse effects more challenging, as noted by The Lancet Diabetes and Endocrinology 2

Specific Risks in This Combination

• Mifepristone blocks cortisol measurements from being reliable for monitoring treatment response or adrenal insufficiency, eliminating a key safety parameter, as reported by The Lancet Diabetes and Endocrinology 1, 2
• If adverse effects occur, mifepristone's long half-life requires several days of stress-dose glucocorticoid replacement, preferably dexamethasone, according to The Lancet Diabetes and Endocrinology 2

Clinical Recommendation Algorithm

• If mifepristone is being considered in a patient on ranolazine, consult an expert endocrinologist with extensive Cushing's disease experience before proceeding, as recommended by The Lancet Diabetes and Endocrinology 1, 2
• Consider alternative medications, such as osilodrostat, metyrapone, or ketoconazole instead of mifepristone for Cushing's disease, or beta-blockers, ivabradine, nitrates, or amlodipine instead of ranolazine, as suggested by The Lancet Diabetes and Endocrinology and the European Heart Journal 1, 2, 3

Common Pitfalls to Avoid

• Do not assume standard monitoring will be adequate - mifepristone eliminates the ability to use cortisol levels for safety monitoring, as warned by The Lancet Diabetes and Endocrinology 1, 2
• Do not prescribe this combination without specialist consultation - guidelines explicitly state mifepristone should only be used by experienced clinicians, according to The Lancet Diabetes and Endocrinology 1, 2